Neurosense Therapeutics Ltd (NRSNW)
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
Giftify’s CardCash Launches Campus Gift Card Exchange Program With Follett Higher Education Campus Bookstores
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Corrective report for a presentation to the capital market - June 2026 - typographical error in the EBITDA data on page 25
Financial Statements and Related Announcement: Full Yearly Results
NUBURU Anticipates Stockholders Equity to Materially Exceed NYSE American Requirement Based on Preliminary May 31 Review
QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week
Performance Shipping Inc. Announces Approval of Amendments Making Its Bonds Senior Unsecured
SUNTEX ENTERPRISES APPOINTS FORMER SPACEX EXECUTIVE TECHNOLOGY SPECIALIST VINCENT ORNELAS TO BOARD OF DIRECTORS
Bonus Issue/ Capitalisation Issue :